Rakuten Aspyrian is a privately funded clinical stage biotechnology company developing tumor-targeted precision therapies based on the new platform Photoimmunotherapy (PIT). PIT is unique in that it combines key advantages of molecular targeting of the cancer cells to achieve high tumor specificity, together with a biophysical mechanism activated at the tumor site to induce rapid cancer cell death.